Daniel Shao-Weng Tan, B.Sc. (Hons), MBBS (London), MRCP (UK), PhD, is a Senior Consultant Medical Oncologist at Division of Medical Oncology at National Cancer Centre Singapore, an Associate Professor (Tenure-Track) at Duke-NUS Medical School, and a Senior Clinician-Scientist at Genome Institute of Singapore. Dr. Tan has a specialist interest in thoracic, head and neck oncology and cancer drug development. Dr Tan’s work is focused on addressing the translational gap between basic science and clinical practice – particularly in improving our understanding of the determinants of response and resistance to targeted therapy and immunotherapy.
In recognition of his research, he received the American Society of Clinical Oncology (ASCO) Merit Award twice, an ASCO Young Investigator Award and the SingHealth GCEO Outstanding Clinician-Researcher Award (2016). In 2019, he was awarded the Daniel C. Idhe Lectureship in Medical Oncology from the International Association for Study of Lung Cancer (IASLC) 2019 for his ‘extensive contributions in the lung cancer arena’. He was twice awarded the Clinician-Scientist Award from the National Medical Research Council of Singapore (NMRC). He has published more than 100 peer-reviewed articles, including top tier journals such as The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, Nature Medicine and Journal of Clinical Oncology.
Dr. Tan received undergraduate training at St Bartholomew’s and Royal London Hospitals in the United Kingdom, obtained First Class honours for an Intercalated BSc in Tumor Biology from University College London (UCL), and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital. In 2017, he completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore.